Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-06-13
2008-12-16
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S258100, C514S269000, C514S274000, C514S275000, C514S252010, C514S252100, C514S336000, C544S253000, C544S299000, C544S323000, C544S326000, C544S333000, C544S334000, C544S335000, C544S238000, C544S239000, C544S240000, C544S241000, C544S336000
Reexamination Certificate
active
07465736
ABSTRACT:
An azole derivative of formula (I)a medicament that contains the azole derivative of formula (I), a method of treating a disease with the azole derivative of formula (I), and a method of preparing the azole derivative of formula (I).
REFERENCES:
patent: 4371734 (1983-02-01), Seybold
patent: 0 169 502 (1986-01-01), None
patent: 1 110 957 (2001-06-01), None
patent: 00/35906 (2000-06-01), None
patent: 00/35909 (2000-06-01), None
patent: 00/35921 (2000-06-01), None
patent: 00/64872 (2000-11-01), None
patent: 01/47920 (2001-07-01), None
patent: 02/10141 (2002-02-01), None
patent: 02/20495 (2002-03-01), None
patent: 02/22608 (2002-03-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3); 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Patel et al. Biochem. Soc. Trans. 32(5), 803-808,2004.
Jope et al., Trends in Biochemical Sciences, 20(2); 95-102, 2004.
Cohen et al., Nature Reviews/Molecular Biology 2: 769-776, 2001.
Turner et al., Current Pharmaceutical Design. 2, 209-224, 1996.
Sugar et al., Diagn. Microbiol. Infect. Dis. 21: 129-133, 1995.
Snyder et al., J. Med. Liban 48(4); 208-214, 2000.
Blyumin et al., Tetrahedron, 58(28), 5733-5740, 2002.
Xie, Xiaoling et al. “Crystal structure of JNK3: a kinase implicated in neuronal apoptosis”, Structure, vol. 6, No. 8, pp. 983-991 1998.
Kumagae, Yoshihiro et al. “Human c-Jun N-terminal kinase expression and activation in the nervous system”, Molecular Brain Research, vol. 67, No. 1, pp. 10-17 1999.
Yang, Derek D. et al. “Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene”, Nature, vol. 389, pp. 865-870 1997.
Yang, Derek D. et al. “Differentiation of CD4+ T Cells to Th1 Cells Requires MAP Kinase JNK2”, Immunity, vol. 9, pp. 575-585 1998.
Sabapathy, Kanaga et al. “JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development”, Current Biology, vol. 9, No. 3, pp. 116-125 1999.
Woodgett, James R. “A common denominator linking glycogen metabolism, nuclear oncogenes and development”, TIBS, vol. 16, pp. 177-181 1991.
Saito, Yuji et al. “The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells”, Biochem. J., vol. 303, pp. 27-31 1994.
Welsh, Gavin I. et al. “Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor elF-2B”, Biochem. J., vol. 294, pp. 625-629 1993.
Cross, Darren A.E. et al. “The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf”, Biochem. J., vol. 303, pp. 21-26 1994.
Grimes, C.A. et al., Progress in Neurobiology, vol. 65, pp. 393-426 2001.
Klein, Peter S. et al. “A molecular mechanism for the effect of lithium on development”, Proc. Natl. Acad. Sci., vol. 93, pp. 8455-8459 1996.
Flueckiger-Isler, Rosina E. et al. “Stimulation of rat liver glycogen synthesis by the adenosine kinase inhibitor 5-iodotubercidin”, Biochem. J., vol. 292, pp. 85-91 1993.
Massillon, Duna et al. “Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor”, Biochem. J., vol. 299, pp. 123-128 1994.
Lovestone, Simon et al. “Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells”, Current Biology, vol. 4, No. 12, pp. 1077-1086 1994.
Brownlees, Janet et al. “Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes”, NeuroReport, vol. 8, pp. 3251-3255 1997.
Stambolic, Vuk et al. “Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells”, Current Biology, vol. 6, No. 12, pp. 1664-1668 1996.
Chen, Guang et al. “The Mood-Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase-3”, Journal of Neurochemistry, vol. 72, pp. 1327-1330 1999.
Takashima, Akihiko et al. “Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau”, Proc. Natl. Acad. Sci., vol. 95, pp. 9637-9641 1998.
Zhang, Zhuohua et al. “Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis”, Nature, vol. 395, pp. 698-702 1998.
Takashima, Akihiko et al. “Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity”, Proc. Natl. Acad. Sci., vol. 90, pp. 7789-7793 1993.
Pei, Jin-Jing et al. “Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain”, Journal of Neuropathology and Experimental Neurology, vol. 56, No. 1, pp. 70-78 1997.
Nonaka, Shigeyuki et al. “Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx”, Proc. Natl. Acad. Sci., vol. 95, pp. 2642-2647 1998.
Thomas, Robert Joseph. “Excitatory Amino Acids in Health and Disease”, JAGS, vol. 43, pp. 1279-1289 1995.
Sasaki, Chihoko et al. “Different expression of glycogen synthase kinase-3beta between young and old rat brains after transient middle cerebral artery occlusion”, Neurological Research, vol. 23, pp. 588-592 2001.
Cross, Darren A.E. “Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death”, Journal of Neurochemistry, vol. 77, pp. 94-102 2001.
Ali, Adnan et al. “Glycogen Synthase Kinase-3: Properties, Functions, and Regulation”, American Chemical Society, pp. A-N 2000.
Naerum, Lars et al. “Scaffold Hopping and Optimization towards Libraries of Glycogen Synthase Kinase-3 Inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 1525-1528 2002.
Chabaka, Laila M. et al. “Facile Synthesis of 2-Furyl-, 2-Pyrrolyl-, 2-Imidazolyl- and Pyrrolo-Azoles from 2-Substituted Methylazoles”, Polish J. Chem., vol. 68, pp. 1317-1325 1994.
Abdelhamid, Abdou O. et al. “Reactions with Hydrazonoyl Halides. Part 10. Formation of Thiohydrazide, Hydrazonoyl Sulfide and Arylazothiazole Derivatives”, J. Chem. Research (S), pp. 144-145 1995.
Brown, Michael D. et al. “A New General Synthesis of 2-(N-Mono- and N-Di-substituted Amino)thiazoles”, J. Chem. Soc. Perkin. Trans. I, vol. 52, No. 5, pp. 1623-1626 1985.
Dawood, Kamal M. et al. “Polyheterocyclic ring systems with bridgehead nitrogen atoms: a facile route to some novel Azolo-1,2,4-triazine derivatives”, J. Chem. Research (S), pp. 206-207 2000.
Gaudry, M. et al. “Enolisation des Cetones Dissymetriques-III”, Tetrahedron, vol. 26, pp. 5611-5615, with English abstract 1970.
“Exploratory Library (Catalog)”, Ambinter, Chemical Abstracts Service, Database accession No. 2002:2290627, XP002218003 2002.
“Exploratory Library (Catalog)”, Ambinter, Chemical Abstracts Service, Database accession No. 2002:2290629, XP002218005 2002.
“Exploratory Library (Catalog)”, Ambinter, Chemical Abstracts Service, Database accession No. 2002:2290615. XP002218009 2002.
Blyumin, E.V. et al. “Reaction of 2-hetarylacetonitriles with ethyl 2-alkylsulfanyl-4-chloro-5-pyrimidinecarboxylates. Synthesis of new condensed pyrimidines”, Tetrahedron, vol. 58, No. 28, pp. 5733-5740, XP004369422 2002.
“Exploratory Library (Catalog)”, Ambinter, Chemical Abstracts Service, Database accession No. 2002:2832472, XP002218001 2002.
“Exploratory Library (Catalog)”
Gaillard Pascale
Gotteland Jean-Pierre
Jeanclaude-Etter Isabelle
Schwarz Matthias
Thomas Russel J.
Balasubram Venkataraman
Laboratoires Serono S.A.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Azole methylidene cyanide derivatives and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azole methylidene cyanide derivatives and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azole methylidene cyanide derivatives and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045647